Pituitary hormones and systemic lupus erythematosus

Arthritis and Rheumatism

Volumn 52, Issue 12, 2005, Pages 3701-3712

  Li, Jing ^a   May, Warren ^a   McMurray, Robert W ^a  

^a UNIVERSITY OF MISSISSIPPI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; AZATHIOPRINE; BROMOCRIPTINE; CORTICOSTEROID; CORTICOTROPIN; CYPROTERONE; CYTOTOXIC AGENT; ESTRADIOL; ESTROGEN; FOLLITROPIN; GROWTH HORMONE; HYDROXYCHLOROQUINE; HYPOPHYSIS HORMONE; INTERLEUKIN 1; INTERLEUKIN 6; LUTEINIZING HORMONE; NONSTEROID ANTIINFLAMMATORY AGENT; ORAL CONTRACEPTIVE AGENT; PRASTERONE; PROLACTIN; TESTOSTERONE; THYROTROPIN; TUMOR NECROSIS FACTOR ALPHA;

AUTOIMMUNITY; CORTICOTROPIN BLOOD LEVEL; DISEASE EXACERBATION; DISEASE SEVERITY; FEMALE; FOLLITROPIN BLOOD LEVEL; GROWTH HORMONE BLOOD LEVEL; HORMONAL REGULATION; HUMAN; HYPOGONADISM; HYPOPHYSIS GONAD SYSTEM; IMMUNOMODULATION; INCIDENCE; LUTEINIZING HORMONE BLOOD LEVEL; LUTEINIZING HORMONE RELEASE; MALE; NONHUMAN; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SYSTEMIC LUPUS ERYTHEMATOSUS; THYROTROPIN BLOOD LEVEL;

ANIMALS; ENDOCRINE SYSTEM DISEASES; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MODELS, STATISTICAL; PITUITARY HORMONES; RISK FACTORS;

EID: 29144448006     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.21436     Document Type: Review

References (64)

1. Whitacre CC, Reingold SC, O'Looney PA. Task force on gender, multiple sclerosis and autoimmunity: a gender gap in autoimmunity. Science 1999;283:1277-8.
2. Wizeman TM, Pardue ML, editors. Exploring the biological contributions to human health: does sex matter? Washington, DC: Committee on Understanding the Biology of Sex and Gender Differences, Institute of Medicine, National Academy Press; 2001. p. 13-238.
3. Lahita RG. Sex hormones and systemic lupus erythematosus. Rheum Dis Clin North Am 2000;26:951-68.
4. Walker SE, Jacobson JD. Roles of prolactin and gonadotropin-releasing hormone in rheumatic diseases. Rheum Dis Clin North Am 2000;26:713-36.
5. McMurray RW, May W. Sex hormones and systemic lupus erythematosus: review and meta-analysis [review]. Arthritis Rheum 2003;48:2100-10.
6. Brook CG, Marshall NJ. Essential endocrinology. 4th ed. London: Blackwell Science; 2001. p. 13-171.
7. Wilson JD, Foster DW. Williams textbook of endocrinology. 8th ed. Philadelphia: WB Saunders Company; 1992.
8. Butts C, Sternberg E. Different approaches to understanding autoimmune rheumatic diseases: the neuroimmunoendocrine system. Best Pract Res Clin Rheumatol 2004;18:125-39.
9. Spangelo BL, Judd AM, Call GB, Zumwalt J, Gorospe WC. Role of the cytokines in the hypothalamic-pituitary-adrenal and gonadal axes. Neuroimmunomodulation 1995;2:299-312.
10. Hermus AR, Sweep CG. Cytokines and the hypothalamic-pituitary-adrenal axis. J Steroid Biochem Mol Biol 1990;37:867-71.
11. Athreya BH, Pletcher J, Zulian F, Weiner DB, Williams WV. Subset-specific effects of sex hormones and pituitary gonadotropins on human lymphocyte proliferation in vitro. Clin Immunol Immunopathol 1993;66:201-11.
12. Jacobson JD, Nisula BC, Steinberg AD. Modulation of the expression of murine lupus by gonadotropin-releasing hormone analogs. Endocrinology 1994;134:2516-23.
13. Jacobson JD, Ansari MA, Kinealy M, Muthukrishnan V. Gender-specific exacerbation of murine lupus by gonadotropin-releasing hormone: potential role of G α(q/11). Endocrinology 1999;140:3429-37.
14. Peeva E, Venkatesh J, Michael D, Diamond B. Prolactin as a modulator of B cell function: implications for SLE. Biomed Pharmacother 2004;58:310-9.
15. McMurray RW. Prolactin in murine systemic lupus erythematosus. Lupus 2001;10:742-7.
16. Lahita RG. Sex, age, and systemic lupus erythematosus. In: Lahita RG, editor. Systemic lupus erythematosus. 2nd ed. New York: Churchill Livingstone; 1992. p. 531-42.
17. Petri M, Buyon JP, Kim M, Kalunian K, Grossman J, Hahn B, et al, and the SELENA Trial Group. Combined oral contraceptives (OC) are not associated with an increased rate of flare in SLE patients in SELENA [abstract]. Arthritis Rheum 2004;50 Suppl 9:S239.
18. Jungers P, Kuttenn F, Liote F, Pelissier C, Athea N, Laurent MC, et al. Hormonal modulation in systemic lupus erythematosus: preliminary clinical and hormonal results with cyproterone acetate. Arthritis Rheum 1985;28:1243-50.
19. Alvarez-Nemegyei J, Cobarrubias-Cobos A, Escalante-Triay F, Sosa-Munoz J, Miranda JM, Jara LJ. Bromocriptine in systemic lupus erythematosus: a double-blind, randomized, placebo-controlled study. Lupus 1998;7:414-9.
20. Ghersevich S, Isomaa V, Vihko P. Cytokine regulation of the expression of estrogenic biosynthetic enzymes in cultured rat granulosa cells. Mol Cell Endocrinol 2001;172:21-30.
21. Salmassi A, Lu S, Hedderich J, Oettinghaus C, Jonat W, Mettler L. Interaction of interleukin-6 on human granulosa cell steroid secretion. J Endocrinol 2001;170:471-8.
22. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1.982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982:25:1271-7.
23. Yozai S. Studies on the secretion of gonadotropins in patients with collagen diseases. Nippon Naibunpi Gakkai Zasshi 1976;52:138-48.
24. Lavalle C, Gonzalez-Barcena D, Graef A. Fraga A. Gonadotropins pituitary secretion in systemic lupus erythematosus. Clin Exp Rheumatol 1984;2:163-5.
25. Arnalich F. Benito-Urbina S. Gonzalez-Gancedo P, Iglesias E, de Miguel E, Gijon-Banos J. Inadequate production of progesterone in women with systemic lupus erythematosus. Br J Rheumatol 1992;31:247-51.
26. Wen C, Li LS. Blood levels of sex hormone in lupus nephritis and their relationship to lupus activity. Chin Med J (Engl) 1993;106:49-52.
27. Munoz JA, Gil A, Lopez-Dupla JM, Vazquez JJ, Gonzalez-Gancedo P. Sex hormones in chronic systemic lupus erythematosus: correlation with clinical and biological parameters. Ann Med Interne (Paris) 1994;145:459-63.
28. Redlich K, Ziegler S, Kiener HP, Spitzauer S, Stohlawetz P, Bernecker P, et al. Bone mineral density and biochemical parameters of bone metabolism in female patients with systemic lupus erythematosus. Ann Rheum Dis 2000;59:308-10.
29. Koeller MD, Templ E, Riedl M, Clodi M, Wagner O, Smolen JS, et al. Pituitary function in patients with newly diagnosed untreated systemic lupus erythematosus. Ann Rheum Dis 2004;63:1677-80.
30. Lavalle C. Loyo E, Paniagua R, Bermudez JA, Herrera J, Graef A, et al. Correlation study between prolactin and androgens in male patients with systemic lupus erythematosus. J Rheumatol 1987;14:268-72.
31. Mackworth-Young CG, Parke AL, Morley KD, Fotherby K, Hughes GR. Sex hormones in male patients with systemic lupus erythematosus: a comparison with other disease groups. Eur J Rheumatol Inflamm 1983;6:228-32.
32. Stahl NI, Decker JL. Androgenic status of males with systemic lupus erythematosus. Arthritis Rheum 1978;21:665-8.
33. Sequeira JF, Keser G, Greenstein B, Wheeler MJ, Duarte PC, Khamashta MA. et al. Systemic lupus erythematosus: sex hormones in male patients. Lupus 1993;2:315-7.
34. Vilarinho ST, Costallat LT. Evaluation of the hypothalamic-pituitary- gonadal axis in males with systemic lupus erythematosus. J Rheumatol 1998;25:1097-103.
35. Chang DM, Chang CC, Kuo SY, Chu SJ, Chang ML. Hormonal profiles and immunological studies of male lupus in Taiwan. Clin Rheumatol 1999;18:158-62.
36. Mok CC, Lau CS. Profile of sex hormones in male patients with systemic lupus erythematosus. Lupus 2000;9:252-7.
37. Folomeev M, Dougados M, Beaune J, Kouyoumdjian JC, Nahoul K. Amor B. et al. Plasma sex hormones and aromatase activity in tissues of patients with systemic lupus erythematosus. Lupus 1992;1:191-5.
38. Lahita RG, Bradlow HL. Fishman J, Kunkel HG. Abnormal estrogen and androgen metabolism in the human with systemic lupus erythematosus. Am J Kidney Dis 1982;2 Suppl 1:206-11.
39. Lahita RG, Bradlow HL, Kunkel HG, Fishman J. Alterations of estrogen metabolism in systemic lupus erythematosus. Arthritis Rheum 1979;22:1195-8.
40. Bulun SE, Noble LS, Takayama K, Michael MD, Agarwal V, Fisher C, et al. Endocrine disorders associated with inappropriately high aromatase expression. J Steroid Biochem Mol Biol 1997;61:133-9.
41. Stratakis CA, Vottero A, Brodie A, Kirschner LS, DeAtkine D, Lu Q. et al. The aromatase excess syndrome is associated with feminization of both sexes and autosomal dominant transmission of aberrant P450 aromatase gene transcription. J Clin Endocrinol Metab 1998;83:1348-57.
42. Greenstein BD, Dhaher YY, Bridges Ede F, Keser G, Khamashta MA, Etherington J, et al. Effects of an aromatase inhibitor on thymus and kidney and on oestrogen receptors in female MRL/ MP-lpr/lpr mice. Lupus 1993;2:221-5.
43. Corwin EJ, Cannon JG. Gonadotropin modulation of interleukin-1 secretion. J Gend Specif Med 1999;2:30-4.
44. Gutierrez MA, Molina JF, Jara LJ, Cuellar ML, Garcia C, Gutierrez-Urena S, et al. Prolactin and systemic lupus erythematosus: prolactin secretion by SLE lymphocytes and proliferative (autocrine) activity. Lupus 1995;4:348-52.
45. Winkler A, Schmidt LG, Rommel Spacher H, Melzig MF. Quantification of proopiomelanocortin mRNA in peripheral lymphocytes of alcoholics. Alcohol 1998;15:43-50.
46. Schurmeyer TH, Tsokos GC, Avgerinos PC, Balow JE, d'Agata R, Loriaux DL, et al. Pituitary-adrenal responsiveness to corticotropin-releasing hormone in patients receiving chronic, alternate day glucocorticoid therapy. J Clin Endocrinol Metab 1985;61:22-7.
47. Iushchishin NI, Zakharov VK, Vitriak AA. [The function of the hypophyseo-adrenal system in patients with disseminated lupus erythematosus.] Vestn Dermatol Venerol 1989;9:38-41. In Russian.
48. Gutierrez MA, Garcia ME, Rodriguez JA, Rivero S, Jacobelli S. Hypothalamic-pituitary-adrenal axis function and prolactin secretion in systemic lupus erythematosus. Lupus 1998;7:404-8.
49. Zietz B, Reber T, Oertel M, Gluck T, Scholmerich J, Straub RH. Altered function of the hypothalamic stress axes in patients with moderately active systemic lupus erythematosus. II. Dissociation between androstenedione, cortisol, or dehydroepiandrosterone and interleukin 6 or tumor necrosis factor. J Rheumatol 2000;27:911-8.
50. Jiang T, Liu S, Tan M, Huang F, Sun Y, Dong X, et al. The phase-shift mutation in the glucocorticoid receptor gene: potential etiologic significance of neuroendocrine mechanisms in lupus nephritis. Clin Chim Acta 2001;313:113-7.
51. Martins JM, Alves J, Trinca A, Grima B, do Vale S, Vasconcelos T, et al. Personality, brain asymmetry, and neuroendocrine reactivity in two immune-mediated disorders: a preliminary report. Brain Behav Immun 2002;16:383-97.
52. Wang HC, Klein JR. Immune function of thyroid stimulating hormone and receptor. Crit Rev Immunol 2001;21:323-37.
53. Ronchezel MV, Len CA, Spinola e Castro A, Sacchetti S, Lourenzi VM, Ajzen S, et al. Thyroid function and serum prolactin levels in patients with juvenile systemic lupus erythematosus. J Pediatr Endocrinol Metab 2001;14:165-9.
54. Mihailova D, Grigorova R, Vassileva B, Mladenova G, Ivanova N, Stephanov S, et al. Autoimmune thyroid disorders in juvenile chronic arthritis and systemic lupus erythematosus. Adv Exp Med Biol 1999;455:55-60.
55. Miller FW, Moore GF, Weintraub BD, Steinberg AD. Prevalence of thyroid disease and abnormal thyroid function test results in patients with systemic lupus erythematosus. Arthritis Rheum 1987;30:1124-31.
56. Konstadoulakis MM, Kroubouzos G, Tosca A, Piperingos G, Marafelia P, Konstadoulakis M, et al. Thyroid autoantibodies in the subsets of lupus erythematosus: correlation with other auto-antibodies and thyroid function. Thyroidology 1993;5:1-7.
57. Velkeniers B, Dogusan Z, Naessens F, Hooghe R, Hooghe-Peters EL. Prolactin, growth hormone and the immune system in humans. Cell Mol Life Sci 1998;54:1102-8.
58. Gala RR. Prolactin and growth hormone in the regulation of the immune system. Proc Soc Exp Biol Med 1991;198:513-27.
59. Rovensky J, Blazickova S, Rauova L, Jezova D, Koska J, Lukac J, et al. The hypothalamic-pituitary response in SLE: regulation of prolactin, growth hormone and cortisol release. Lupus 1998;7:409-13.
60. Bae YS, Bae SC, Lee SW, Yoo DH, Kim TY, Kim SY. Lupus flare associated with growth hormone. Lupus 2001;10:448-50.
61. Ingvarsson CG. Prolactin in rheumatoid arthritis (a therapeutic test). Acta Rheumatol Scand 1969;15:4-17.
62. Walker SE, Reddy GH, Miller D, Yangco D, Kalanje S, Abdou NI, et al. Treatment of active systemic lupus erythematosus (SLE) with the prolactin (PRL) lowering drug, bromocriptine (BC): comparison with hydroxychloroquine (HC) in a randomized, blinded one-year study [abstract]. Arthritis Rheum 1999:42 Suppl 9:S282.
63. Athreya BH, Rafferty JH, Sehgal GS, Lahita RG. Adenohypophyseal and sex hormones in pediatric rheumatic diseases. J Rheumatol 1993;20:725-30.
64. Masi AT, Bijlsma JW, Chikanza IC, Pitzalis C, Cutolo M. Neuroendocrine, immunologic, and microvascular systems interactions in rheumatoid arthritis: physiopathogenetic and therapeutic perspectives. Semin Arthritis Rheum 1999;29:65-81.